Physician profile
Thomas Watson
NPI 1790741833
$5,339.26
in general payments reported to CMS, 2019-2025
20 companies · $3,363 in 2025
The $3,363 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $267 · 2021: $204 · 2022: $174 · 2023: $325 · 2024: $268 · 2025: $3,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,016 · Food and Beverage: $902 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,015.52 |
| Food and Beverage | $901.69 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $3,520.45 | 2021-2025 | Optiflux, Liberty Select Cycler, Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $432.73 | 2019-2024 | Farxiga |
| Vifor Pharma, INC. | $265.78 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $261.44 | 2019-2023 | Soliris, Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $152.23 | 2022-2024 | |
| Akebia Therapeutics INC | $111.69 | 2019-2023 | Auryxia |
| Amgen INC. | $98.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $71.41 | 2020-2023 | Jynarque |
| Glaxosmithkline, LLC. | $67.25 | 2023 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $59.55 | 2023 | Krystexxa |
| Bard Peripheral Vascular, INC. | $56.23 | 2020 | |
| Mallinckrodt Enterprises LLC | $53.04 | 2019 | |
| Travere Therapeutics, INC. | $40.63 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $34.71 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $24.65 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $22.81 | 2019 | |
| Baxter Healthcare | $19.63 | 2024 | Renal - Acute |
| Aurinia Pharma U.S., INC. | $17.10 | 2021 | |
| Argon Medical Devices, INC. | $14.64 | 2019 | |
| Medtronic, INC. | $14.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.